$0.97 +0.03 (%) Cytori Therapeutics Inc - NASDAQ

Sep. 19, 2014 | 10:10 AM

Partner Headlines

  1. Stocks Hitting 52-Week Lows

    Benzinga | Aug. 22, 2014 | 10:36AM EST
  2. Ascendiant Downgrades Cytori Therapeutics As ATHENA Trials Are Put On Hold

    Benzinga | Aug. 6, 2014 | 11:31AM EST
  3. Stocks Hitting 52-Week Lows

    Benzinga | Aug. 6, 2014 | 10:26AM EST
  4. Morning Market Losers

    Benzinga | Aug. 6, 2014 | 10:00AM EST
  5. Benzinga's Top Downgrades

    Benzinga | Aug. 6, 2014 | 09:13AM EST
  6. Ascendiant Capital Downgrades Cytori Therapeutics To Hold

    Benzinga | Aug. 6, 2014 | 07:41AM EST
  7. UPDATE: Cytori Says It has Placed Enrollment in Athena On Hold and Puts Athena II Trials On Clinical Hold

    Benzinga | Aug. 5, 2014 | 16:07PM EST
  8. Morning Market Movers

    Benzinga | Jul. 7, 2014 | 09:37AM EST
  9. Cytori Announces Senior Management Changes; Christopher Calhoun CEO and Director of Cytori Therapeutics, is Retiring as CEO of the Company, Effective Immediately

    Benzinga | Apr. 2, 2014 | 16:07PM EST
  10. Cytori Receives IDE Approval from FDA to Initiate US Clinical Trial of Adipose-Derived Regenerative Cells in Hamstring Injuries

    Benzinga | Jan. 13, 2014 | 08:29AM EST
  11. Cytori Receives $12M First Installment from Lorem Vascular Partnership Equity Agreement

    Benzinga | Nov. 7, 2013 | 12:43PM EST
  12. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 5, 2013 | 08:11AM EST
  13. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 10, 2013 | 08:09AM EST
  14. Cytori's Celution® System Approved in Australia for Processing and Delivering Adipose-Derived Regenerative Cells

    Benzinga | Aug. 7, 2013 | 08:07AM EST
  15. Morning Market Losers

    Benzinga | Dec. 14, 2012 | 03:04AM EST
  16. Cytori Awarded Contract Valued up to $106 Million by Biomedical Advanced Research and Development Authority

    Benzinga | Sep. 28, 2012 | 01:32AM EST
  17. Cytori Therapeutics Inc Reports Operating Results (10-Q)

    GuruFocus | Aug. 9, 2012 | 12:29PM EST
  18. Cytori Provides Strategic Outlook, Near Term Objectives

    Benzinga | Mar. 8, 2012 | 09:13AM EST
  19. Notable Put Options Activity in Cytori Therapeutics

    Benzinga | Mar. 5, 2012 | 06:00AM EST
  20. Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun sells 205,000 Shares

    GuruFocus | Feb. 6, 2012 | 10:50AM EST
Trading Center